ICU Medical, Inc. (NASDAQ:ICUI) Stock Position Decreased by Corient Private Wealth LLC

Corient Private Wealth LLC cut its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 61.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,233 shares of the medical instruments supplier’s stock after selling 3,578 shares during the period. Corient Private Wealth LLC’s holdings in ICU Medical were worth $346,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Charles Schwab Investment Management Inc. grew its stake in ICU Medical by 10.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 301,107 shares of the medical instruments supplier’s stock valued at $54,868,000 after acquiring an additional 27,927 shares in the last quarter. Citigroup Inc. increased its stake in ICU Medical by 100.4% in the 3rd quarter. Citigroup Inc. now owns 28,965 shares of the medical instruments supplier’s stock valued at $5,278,000 after buying an additional 14,512 shares during the period. Cerity Partners LLC lifted its position in ICU Medical by 33.2% in the 3rd quarter. Cerity Partners LLC now owns 9,846 shares of the medical instruments supplier’s stock worth $1,794,000 after buying an additional 2,454 shares in the last quarter. FMR LLC boosted its stake in shares of ICU Medical by 2,676.6% during the 3rd quarter. FMR LLC now owns 104,094 shares of the medical instruments supplier’s stock valued at $18,968,000 after buying an additional 100,345 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in shares of ICU Medical by 16.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 6,997 shares of the medical instruments supplier’s stock valued at $1,275,000 after acquiring an additional 991 shares in the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other ICU Medical news, CEO Vivek Jain sold 1,373 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total value of $213,474.04. Following the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $16,262,119.64. This trade represents a 1.30 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 6.70% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Raymond James set a $97.00 target price on ICU Medical in a research report on Wednesday, March 12th. Jefferies Financial Group upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective on the stock in a report on Wednesday, December 11th. Finally, StockNews.com cut shares of ICU Medical from a “buy” rating to a “hold” rating in a research note on Thursday. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $168.67.

ICU Medical Stock Performance

Shares of NASDAQ ICUI opened at $140.16 on Monday. The business’s 50-day simple moving average is $154.42 and its 200-day simple moving average is $163.78. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. ICU Medical, Inc. has a 52 week low of $93.36 and a 52 week high of $196.26. The firm has a market cap of $3.44 billion, a price-to-earnings ratio of -30.67 and a beta of 0.73.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.